Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI Intensification in High-risk Locally Advanced Rectal Cancer
NCT03997435Phase 2Active, not recruiting
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Sep 2019
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of FOLFIRINOX in rectal cancer (2 arms), sponsored by Cambridge Clinical Trials Unit. Primary endpoint: Pathologic Complete Response at 2 years. Started Sep 2019; status: active, not recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03997435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997435.